Frontage Holdings (HKSE:01521) Common Stock : HK$0 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Common Stock?

Frontage Holdings's quarterly common stock stayed the same from Jun. 2023 (HK$0 Mil) to Dec. 2023 (HK$0 Mil) but then declined from Dec. 2023 (HK$0 Mil) to Jun. 2024 (HK$0 Mil).

Frontage Holdings's annual common stock increased from Dec. 2021 (HK$0 Mil) to Dec. 2022 (HK$0 Mil) and increased from Dec. 2022 (HK$0 Mil) to Dec. 2023 (HK$0 Mil).

Frontage Holdings Common Stock Historical Data

The historical data trend for Frontage Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Common Stock Chart

Frontage Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.16

Frontage Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial										0.17	0.16	0.16	0.16	0.16

Frontage Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frontage Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Pennsylvania Drive, Exton, PA, USA, 19341

Website

https://www.frontagelab.com

Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical, and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include drug discovery, drug development, pharmaceutical product development, and laboratory testing in the USA and Canada; and the PRC segment includes the same services provided in the People's Republic of China. The company generates a majority of its revenue from USA followed by the PRC and the rest of the world.

Executives

Hang Zhou Tai Ge Yi Yao Ke Ji Gu Fen You Xian Gong Si	2101 Beneficial owner
Li Song	2101 Beneficial owner
Kabouter Management Llc	2102 Investment manager
Hangzhou Tigermed Consulting Co., Ltd.
Hongkong Tigermed Co., Limited

Frontage Holdings Headlines

No Headlines